FOLH1 and prostate cancer: Wei et al. observed significant tumor regression and decreased PSMA expression in cerebral lesions based on 68Ga-PSMA PET/CT imaging performed after 177Lu-PSMA-617 treatments combined with radiotherapy in two prostate cancer patients with cerebral metastasis [25].